Haemonetics is Celebrating International Plasma Awareness Week

3RD ANNUAL INTERNATIONAL PLASMA AWARENESS WEEK CELEBRATES PLASMA DONORS

News provided by

Oct 15, 2015, 07:00 ET

BRAINTREE, Mass., Oct. 15, 2015 /PRNewswire/ -- Haemonetics is celebrating the third annual International Plasma Awareness Week October 11-17. A joint initiative of the Plasma Protein Therapeutics Association (PPTA) and its member companies, IPAW is designed to:

Raise awareness about plasma donation
Recognize the contributions of plasma donors in saving and improving lives
Increase understanding about lifesaving plasma protein therapies and rare diseases

Member companies are planning a variety of activities including: donor appreciation events and open houses for patients, government officials, and the media at more than 500 plasma collection facilities in the U.S. and Europe.

Haemonetics is passionate about raising global awareness of plasma collection and recognizing the contributions of plasma donors to saving and improving lives. "For more than 40 years, Haemonetics has been committed to the plasma industry, serving them in their mission to provide life-saving plasma therapies to patients around the world," Thomas McCurdy, President Global Plasma, Haemonetics

Plasma, a biological material that cannot be manufactured, is used to create lifesaving therapies that come solely from committed plasma donors. Haemonetics' innovative, integrated solutions ensure safe and efficient plasma collection. Last year, Haemonetics devices collected over 25 million global plasma donations!

As Haemonetics celebrates the generosity of plasma donors and raises awareness for the rare diseases that are treated with the therapies during IPAW, we encourage everyone to thank donors who help to ensure a higher quality of life for patients around the world.

Plasma protein therapies, which include plasma-derived therapies and recombinant analogs are used to treat chronic, life-threatening diseases including bleeding disorders alpha-1 antitrypsin deficiency and certain rare neurological disorders. In addition, these therapies are used in emergency and surgical medicine.

Learn more about plasma protein therapies, the diseases they treat and Donating Plasma, please visit www.donatingplasma.org

About Haemonetics: Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com

About Plasma Donation: Plasma, a biological material that cannot be manufactured, is used to create lifesaving therapies that come solely from committed plasma donors. Plasma protein therapies, which include plasma-derived therapies and recombinant analogs are used to treat chronic, life-threatening diseases including bleeding disorders alpha-1 antitrypsin deficiency and certain rare neurological disorders. In addition, these therapies are used in emergency and surgical medicine. To learn more about plasma protein therapies, the diseases they treat and Donating Plasma, please visit www.donatingplasma.org

CONTACT:
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
[email protected]

Laura Steele, Senior Manager Communications
Tel. (781) 356-9747
[email protected]

Logo - http://photos.prnewswire.com/prnh/20150128/172006LOGO

SOURCE Haemonetics Corporation